Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2

A. Huibers a,c, A. Halliday a,*, R. Bulbulia b, G. Coppi d, G.J. de Borst e, on behalf of the ACST-2 Collaborative Group

a Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
b Clinical Trial Service Unit, University of Oxford, Oxford, UK
c Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
d Department of Vascular Surgery, Nuovo Ospedale S. Agostino Estense, University of Modena, Modena, Italy

WHAT THIS PAPER ADDS

Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks. There are currently no specific guidelines on dose and duration of peri-procedural antiplatelet treatment to help clinical proposal design for patients undergoing carotid intervention. The Asymptomatic Carotid Surgery Trial-2 (ACST-2) is the largest clinical trial of interventional treatment for asymptomatic carotid disease, randomising patients to either carotid endarterectomy (CEA) or carotid artery stenting (CAS). The present study reports the “real-world” practice in peri-procedural antiplatelet therapy among collaborators in ACST-2.

Objective: Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks. There are currently no specific guidelines on dose or duration of peri-procedural antiplatelet treatment for patients undergoing carotid intervention. Within the ongoing Asymptomatic Carotid Surgery Trial-2 (ACST-2), this study aimed at assessing the current use of antiplatelet therapy before, during, and after CEA and CAS in patients with asymptomatic carotid stenosis.

Methods: Questionnaires were sent to ACST-2 collaborators seeking information about the use of antiplatelet therapy during the pre-, peri-, and post-operative periods in patients undergoing carotid intervention at 77 participating sites and also whether sites tested for antiplatelet therapy resistance.

Results: The response rate was 68/77 (88%). For CAS, 82% of sites used dual antiplatelet therapy (DAPT) pre-operatively and 86% post-operatively with a mean post-procedural duration of 3 months (range 1–12), while 9% continued DAPT life-long. For CEA only 31% used DAPT pre-operatively, 24% post-operatively with a mean post-procedural duration of 3 months (range 1–5), while 10% continued DAPT life-long. For those prescribing post-procedural mono antiplatelet (MAPT) therapy (76%), aspirin was more commonly prescribed (59%) than clopidogrel (6%) and 11% of centres did not show a preference for either aspirin or clopidogrel. Eleven centres (16%) tested for antiplatelet therapy resistance.

Conclusion: There appears to be broad agreement on the use of antiplatelet therapy in ACST-2 patients undergoing carotid artery stenting and surgery. Although evidence to help guide the duration of peri-procedural antiplatelet therapy is limited, long-term treatment with DAPT appears similar between both treatment arms.

INTRODUCTION

Stroke is a leading cause of morbidity and mortality worldwide.1 Randomised trials in patients with carotid artery narrowing have shown that carotid endarterectomy (CEA) with medical treatment reduces 5 and 10 year stroke risk compared with medical treatment alone.2,3 A feared peri-operative complication is embolism from the narrowed carotid plaque leading to distal vascular occlusion and ischaemic stroke.4,5 Antiplatelet therapy reduces the risk of occlusive vascular events, but can also cause bleeding (the risk of which may be increased substantially with more intensive regimens).6,7 There are no specific guidelines on dose and duration on peri-procedural antiplatelet treatment to help clinical proposal design for patients undergoing carotid intervention.8,9 In previous carotid trials comparing CEA and CAS, single antiplatelet therapy (usually...
aspirin) was used for CEA, and dual antiplatelet therapy (usually clopidogrel and aspirin) was either recommended or mandated.10–12

The Asymptomatic Carotid Surgery Trial-2 (ACST-2) is the largest clinical trial of interventional treatment for asymptomatic carotid disease, randomising patients to either CEA or carotid artery stenting (CAS). ACST-2 will compare the immediate hazards of both procedures and subsequent stroke rates over the next 5–10 years.13 Collaborators from 26 countries worldwide are experienced surgeons and interventionists, and the choice of peri-procedural antiplatelet treatment is at the clinicians’ discretion. This gives a unique opportunity to study “real-world” practice in peri-procedural antiplatelet therapy. Therefore, the aim of the present study was to describe the use of antiplatelet therapy for both carotid surgery and stenting among collaborators in the ACST-2 trial.

METHODS

ACST-2

The aims and methods used in ACST-2 have been described previously.14 Briefly, patients with severe asymptomatic carotid stenosis in which revascularisation is felt to be indicated, are randomised in a 1:1 fashion between CAS and CEA. The trial is multicentre and international, thereby facilitating large-scale recruitment of an appropriately heterogeneous and representative group. However, the majority of recruiting centres (93%) are located in Europe and therefore the study largely reflects antiplatelet therapy in Europe. The trial protocol states that all patients should receive appropriate medical treatment, including antiplatelet therapy, but the use and dose of specific antiplatelet drugs (and other drugs) are left to the discretion of the treating physician.

Study

This study questionnaire was administered in August 2014 and addressed four areas of practice: (1) pre-procedural antiplatelet therapy (in CAS and CEA); (2) intra-procedural antiplatelet therapy (CAS and CEA); (3) post-procedural antiplatelet therapy (CAS and CEA); and (4) testing of antiplatelet resistance; Collaborators who failed to respond were sent a reminder e-mail to participate in the study after 4 and 8 weeks. Seventy-seven of the currently active and recruiting centres in ACST-2 were studied; these studies had recruited a total of 1645 patients to ACST-2. In these centres, 75 performed both CAS and CEA and two performed CEA only.

Statistical analysis

Statistical analysis was performed using SPSS (IBM version 22, 2013). If an answer to duration of antiplatelet therapy was given as a range, the midpoint was taken for the subsequent analysis. Chi-square test was applied to compare pre-, intra- and post-procedural antiplatelet therapy, and a Mann-Whitney U test was used to compare means between two treatments. A p-value was considered significant when <.05.

RESULTS

Response

This study was completed in 66 of 75 centres (88% for CAS) and 61 of 77 centres (79% for CEA). These centres had randomised 1407/1645 patients in ACST-2 (85% of the overall randomisation) from 20 different countries.

Carotid artery stenting

Nearly all responding collaborators who performed CAS had a specific protocol for pre-procedural antiplatelet therapy (65/66 [98%]). The majority treated patients with dual antiplatelet therapy (DAPT) prior to stenting (53/65 [82%]). In nearly all centres (52/53 [98%]) DAPT consisted of aspirin and clopidogrel. One centre prescribed aspirin in combination with either clopidogrel or ticagrelor. Other pre-procedural treatment regimens consisted of aspirin only (3/65 [5%]), clopidogrel only (6/65 [8%]), or triple antiplatelet therapy (3/65 [5%]).

During CAS, all patients received heparin and pre-procedural antiplatelet therapy was continued. One centre also routinely used intra-procedural dextran.

After stenting, all patients received at least aspirin or clopidogrel as life-long therapy. The majority of centres (51/66 [77%]) used DAPT for a defined period post-stenting, followed by life-long single antiplatelet therapy. The drug of preference for life-long treatment was aspirin in 68% of the centres (45/66) and clopidogrel in 6/66 centres (9%). In 51 centres, 12 (24%) administered DAPT for up to 4 weeks and 39 centres (76%) extended DAPT beyond the procedural period (median 3; range 1–12 months). A small proportion of respondents stated that they would give life-long DAPT (6/66 [9%]) or just use life-long single antiplatelet therapy (5/66 [8%]). Four centres treated patients with 9 months of prasugrel or cilostazol (4/66 [6%]) in addition to DAPT (Table 1).

Carotid endarterectomy

For CEA, collaborators had a protocol for pre-operative antiplatelet therapy protocol in 55 out of the 61 responding centres (90%). The remaining six centres continued baseline therapy at randomisation.

Prior to the procedure, most patients received aspirin as single antiplatelet therapy (36/55 [65%]). In 17 centres (31%) dual antiplatelet therapy was used. The number of centres that prescribed DAPT prior to CEA was significantly lower than the use of DAPT prior to CAS (p < .05). DAPT consisted of aspirin and clopidogrel in 14 centres. Three centres prescribed aspirin in combination with dipyridamole. In one centre (2%) clopidogrel was used as a single antiplatelet agent. Other pre-procedural treatments consisted of triple antiplatelet therapy in one centre. Patients undergoing CEA received similar intra-operative antiplatelet treatment to patients undergoing CAS: in all centres heparin
was administered and pre-procedural antiplatelet therapy was continued. The same centre that routinely prescribed dextran during the CAS procedure also prescribed dextran during CEA. Post-procedurally, centres used life-long aspirin or clopidogrel for all CEA patients, similar to present findings in the CAS group. Fifteen centres (24%) prescribed DAPT after CEA, and usually for a defined period; thus the use of DAPT after surgery was significantly lower than after CAS ($p < .05$). Six of 61 centres (10%) continued dual antiplatelet therapy life-long. Of the remaining nine centres, two prescribed DAPT for up to 4 weeks and seven extended the use of DAPT beyond the procedural period (median 3; range 1–5 months). The median duration of DAPT use was not significantly different between CAS and CEA ($p = .74$). The drug of choice for life-long use following CAS was aspirin.

### Regional variation

Table S1 (supplementary material) gives an overview of participating countries in this survey and their pre-and post-procedural antiplatelet therapy for CAS and CEA. Fig. 1 shows the prescription rates described within different regions. Before the procedure antiplatelet treatment regimens did not vary widely between different regions (Figs. 1A, C). Post CAS, life-long DAPT was more often prescribed in Western Europe compared with other regions (Fig. 1B). After CEA, all centres in Northern Europe prescribed MAPT therapy, all Eastern European centres prescribed DAPT, whereas both MAPT and DAPT treatments regimens were used in other countries (Fig. 1D).

### Antiplaetle resistance

A small proportion (11/68; 16%) of responding centres performs platelet function tests for detection of resistance to antiplatelet drugs. Eleven centres tested for resistance to aspirin. In addition, six of these 11 centres also tested for clopidogrel resistance. The current survey was not designed to answer the question of how centres tailored their procedural antiplatelet therapy based on platelet function tests.

### DISCUSSION

In this study describing the use of antiplatelet therapies by collaborators in ACST-2 during the pre- and post-procedural periods, most patients undergoing CAS were treated with DAPT, whereas patients undergoing CEA received a single antiplatelet drug. Intra-operative regimens were similar for both procedures, all collaborators using heparin and continued antiplatelet therapy. After the procedures, more CAS than CEA patients received DAPT, and the median duration of DAPT (30 days) was similar for both procedures. This is the first large survey comparing pre-, intra- and post-procedural antiplatelet therapy for CAS and CEA. Previous surveys addressing procedural antiplatelet treatment have focused on vascular surgical procedures in general, on only carotid endarterectomy or on technical aspects of the procedure. In 2009, in a survey of 650 European surgeons, Hamish et al. found broad agreement between vascular surgeons in the peri-procedural management of patients undergoing CEA. For symptomatic patients and asymptomatic patients 95% and 88% of surgeons would continue aspirin prior to CEA. Of those surgeons prescribing clopidogrel, about half would stop this drug prior to treatment. The present survey allowed assessment of antiplatelet variations across regions. More variation existed in post-procedural treatment. For CAS, DAPT was more often prescribed in Western Europe. Following CEA, all centres in Northern Europe prescribed MAPT, all Eastern European centres prescribed DAPT, whereas patients undergoing CEA received a single antiplatelet drug. Intra-operative regimens were similar for both procedures, all collaborators using heparin and continued antiplatelet therapy. After the procedures, more CAS than CEA patients received DAPT, and the median duration of DAPT (30 days) was similar for both procedures.

### Table 1. Peri-procedural antiplatelet therapy for carotid artery stenting (CAS) and carotid endarterectomy (CEA) among 68 centres.

<table>
<thead>
<tr>
<th>Pre-procedural</th>
<th>CAS (n = 66)</th>
<th>CEA (n = 61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you have a pre-procedural protocol?</td>
<td>Yes (98%)</td>
<td>Yes (90%)</td>
</tr>
<tr>
<td>Do you generally give?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAPT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>5%</td>
<td>65%</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>8%</td>
<td>2%</td>
</tr>
<tr>
<td>DAPT</td>
<td>82%</td>
<td>31%</td>
</tr>
<tr>
<td>TAPT</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td>Intra-procedural</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do you generally give?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin + continued antiplatelet</td>
<td>98%</td>
<td>98%</td>
</tr>
<tr>
<td>Dextran additionally</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Post-procedural</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do you generally give?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAPT</td>
<td>86%</td>
<td>24%</td>
</tr>
<tr>
<td>MAPT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>6%</td>
<td>59%</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>1%</td>
<td>6%</td>
</tr>
<tr>
<td>Aspirin or clopidogrel (no preference)</td>
<td>1%</td>
<td>11%</td>
</tr>
<tr>
<td>TAPT</td>
<td>6%</td>
<td>0%</td>
</tr>
<tr>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAPT (aspirin or clopidogrel)</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>MAPT life-long</td>
<td>9%</td>
<td>10%</td>
</tr>
<tr>
<td>DAPT for (median; range)</td>
<td>77% (3; 1–12)</td>
<td>14% (3; 1–5)</td>
</tr>
<tr>
<td>then aspirin life-long</td>
<td>68%</td>
<td>14%</td>
</tr>
<tr>
<td>then clopidogrel life-long</td>
<td>9%</td>
<td>0%</td>
</tr>
</tbody>
</table>

| Resistance | |
| Do you test for antiplatelet resistance? | Yes | 11/68 centres (16%) |
| Aspirin | 6 centres |
| Clopidogrel | 11 centres |

MAPT = mono antiplatelet therapy; DAPT = dual antiplatelet therapy; TAPT = triple antiplatelet therapy. The current survey was not designed to answer the question of how centres tailored their procedural antiplatelet therapy based on platelet function tests.
Figure 1. Pre- (A, C) and post-procedural (B, D) antiplatelet therapy per region.
Despite aspirin therapy and adequate heparinisation, thromboembolic stroke still occurs in the peri-procedural period. Therefore, the addition of an antiplatelet drug acting through a different pathway may be of more benefit than aspirin alone. The results of two small studies seem to support this hypothesis and report that a single dose of 75 mg clopidogrel (administered the night before surgery) significantly reduced transcranial detected cerebral embolisation post CEA. However, most of these patients (84%) were symptomatic. In the present study of asymptomatic patients, 30% of surgeons prescribe DAPT therapy prior to CEA.

In carotid artery stenting, two mechanisms can cause peri-procedural thromboembolic stroke: (1) distal embolisation from a destabilised carotid plaque and (2) thrombus formation following intimal injury. Protection devices have been developed to try to reduce distal embolisation but, for the second proposed mechanism, antiplatelet therapy plays an important role. In the present study the majority of interventionists prescribe DAPT before and after CAS. A dual antiplatelet regime has been shown to reduce adverse events without increasing bleeding in several small studies and is now considered to be routine pre-operative practice during CAS. The optimal duration for DAPT post stenting is less well established, but treatment for at least 4 weeks is usually recommended. As coronary intervention has a longer history than CAS, the standard peri-procedural antithrombotic therapy is mainly based on large comparative studies in coronary intervention. In the present survey, 39 centres (76%) extended therapy well beyond the procedural period and 9% administered life-long DAPT. Stent endothelialisation takes some time and late stent thrombosis (>30 days) has been reported in coronary artery stenting, with an annual rate reported ranging from 0.6% to 1.6%. Prolonged use of clopidogrel and aspirin has also been associated with a decrease in long-term major vascular events. It may be important in the future to try to define the optimal duration of dual antiplatelet therapy for carotid artery stenting. Furthermore, this lack of evidence should be made clear in the current guidelines that lead the present clinical practice.

Currently, there is also ongoing interest in the role of antiplatelet reactivity testing in carotid revascularisation. A recent review, including 102 studies (on 44,098 patients) showed that high on-treatment platelet reactivity (HPR), recently reviewed, including 102 studies (on 44,098 patients) antiplatelet reactivity testing in carotid revascularisation. A lead the present clinical practice.

In conclusion, despite the lack of guidelines, there appears to be a broad agreement among ACST-2 collaborators on the long-term use of antiplatelet therapy patients undergoing carotid artery stenting and surgery. However, in the early post-procedural period some variation exists, with more CAS patients receiving DAPT.

ACKNOWLEDGEMENTS

We thank the patients who agreed to participate, and the many collaborating doctors and trial staff. A special acknowledgement to the collaborating centres that participated in this survey. Belgium (62 patients): University Hospital of Antwerp, Cliniques Universitaires St-Luc, Imelda Hospital, Universitair Ziekenhuis Gent. Canada (10 patients): Foothills Medical Centre. Czech Republic (58 patients): University Hospital Ostrava Poruba, St Anne’s University Hospital Brno, Ceske Budejovice — Budweis, Regional Hospital Liberec. Estonia (10 patients): East Tallinn Central Hospital. Germany (44 patients): Städtisches Klinikum Karlsruhe, Klinikum rechts der Isar der Technischen Universität Muenchen, Hegau-Bodensee-Klinikum, Universitätsklinikum Hamburg-Eppendorf, St Franziskus Hospital Münster. Greece (37 patients): University Hospital of Larissa, Vascular Unit — 3rd Surgical Department, Attikon University Hospital. Hungary (44 patients): Semmelweis Medical University, Albert Szent-Györgyi Medical Centre. Israel (13 patients) Rambam Medical Centre. Italy (381 patients): IRCCS Policlinico San Donato, Santa Maria Hospital, Policlinico Catania, University La Sapienza, Policlinico Santa Maria Alle Scotte, Circolo University Hospital, Vascular Endovascular Unit of Perugia, Umberto I- ASO Mauriziano, Istituto Auxologico Italiano, Nuovo Ospedale Civile Sant’ Agostino Estense Modena, San Camillo Forlanini, San Giacono Hospital, Ospedale San Francesco di Nuoro. Japan (1 patient): Sendai Medical Centre. The Netherlands (47 patients): MCL Leeuwarden, University Hospital Utrecht, Rijnstate Hospital, HagaZiekenhuis Locatie Leyenburg. Norway (8 patients): Rikshospitalet University Hospital. Poland (59 patients): Central Hospital Internal Affairs & Admin Ministry, Medical University Hospital of Warsaw, Poznan University of Medical Sciences. Russia (28 patients): Novosibirsk Research Institute of Circulation Pathology. Serbia (167 patients): Dedinje Cardiovascular Unit, Serbian Clinical Centre. Slovenia (20 patients): Teaching Hospital Maribor.
Izola General Hospital. Spain (35 patients): Hospital Clinic 1 Provincial De Barcelona, Guadalajara Hospital. Sweden (167 patients): Sodersjukhuset, Malmo Vascular Centre, Helsingborg Lasarettet. Switzerland (21 patients): University of Basel. United Kingdom (195 patients): Derriford Hospital, John Radcliffe Hospital, Hull Royal Infirmary, Freeman Hospital, University Hospital of North Durham, Kent and Canterbury Hospital, Sheffield Vascular Institute, St Mary’s Hospital, Wythenshawe Hospital University of South Manchester, The Royal Preston Hospital, Nottingham University Hospital, Sunderland Royal Hospital.

CONFLICT OF INTEREST
None.

FUNDING
The research was supported by the National Institute for Health Research (NIHR) Health Technology Assessment 06/301/233, and Professor Halliday’s research is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford.

APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.ejvs.2015.11.002.

REFERENCES


